Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer

Archives of Surgery

Volumn 144, Issue 9, 2009, Pages 835-839

  Kumar, Sandeep ^a   Chang, Eugene Y ^a   Frankhouse, Joseph ^b   Dorsey, Paul B ^b   Lee, Randall G ^b   Johnson, Nathalie ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b LEGACY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; HUMANS; LYMPHOCYTES; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70349451599     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2009.162     Document Type: Article

References (20)

1. Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Chang EY, Dorsey PB, Johnson N, et al. A prospective analysis of microsatellite instability as a molecular marker in colorectal cancer. Am J Surg. 2006;191 (5):646-651.
3. Peltomäki P. The genetics of hereditary non-polyposis colorectal cancer and non-polypotic colon cancer. Adv Exp Med Biol. 1999;470:95-98.
4. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248-5257.
5. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964. (Pubitemid 44498003)
6. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994;145(1):148-156. (Pubitemid 24217493)
7. Risio M, Reato G, di Celle PF, Fizzotti M, Rossini FP, Foà R. Microsatellite instability is associated with the histological features of the tumor in nonfamilial colorectal cancer. Cancer Res. 1996;56(23):5470-5474. (Pubitemid 27011382)
8. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158(2):527-535. (Pubitemid 32158613)
9. Jass JR. Pathology of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci. 2000;910:62-74. (Pubitemid 30462058)
10. Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154(6):1805-1813. (Pubitemid 29262862)
11. Chang EY, Dorsey PB, Frankhouse J, et al. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer. Arch Surg. 2009;144(6):511-515.
12. NIH consensus conference: adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264(11):1444-1450.
13. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-3419. (Pubitemid 41103700)
14. Wolmark N, Wieand HS, Rockette HE, et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer: findings from the NSABP clinical trials. Ann Surg. 1983;198(6):743-752. (Pubitemid 14202751)
15. Müller A, Giuffre G, Edmonston TB, et al; German HNPCC Consortium German Cancer Aid (Deutsche Krebshilfe). Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. J Mol Diagn. 2004;6(4):308-315.
16. Wright CM, Dent OF, Barker M, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg. 2000;87(9):1197-1202. (Pubitemid 30695466)
17. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-257.
18. Grothey A, Sargent D. FOLFOX for stage II colon cancer? a commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol. 2005;23(15):3311-3313. (Pubitemid 46243474)
19. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol. 2003;14(7):1026-1038. (Pubitemid 36950166)
20. André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.